You are here: Industry Insights > NICE

News List

New NICE guidance recommends inducing women in labour earlier pharmatimes
May 26, 2021
Draft guidelines published by the UK’s National Institute for Health and Care Excellence (NICE) has recommended inducing women in labour earlier in order to ‘make birth safer’.
UK patients with rare blood disorders receive new treatment option europeanpharmaceuticalreview
May 21, 2021
NICE has recommended that Ultomiris (ravulizumab) be available on the NHS for patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome.
NICE turns down Janssen's Erleada pharmatimes
May 21, 2021
The National Institute for Health and Care Excellence (NICE) has published draft guidance rejecting Janssen's Erleada (apalutamide) with androgen deprivation therapy (ADT) for treating prostate cancer.
NICE nod for BMS’ Opdivo in advanced oesophageal cancer pharmatimes
May 17, 2021
The UK National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb’s (BMS) Opdivo for the treatment of unresectable advanced oesophageal squamous cell cancer (OSCC).
Keytruda wins NICE backing in MSI-H/dMMR colorectal cancer pharmatimes
May 17, 2021
MSD’s immunotherapy Keytruda has gained UK National Institute for Health and Care Excellence (NICE) backing as a first-line treatment for certain colorectal cancer patients.
UK NICE rejects NHS use of ozanimod for MS treatment pharmaceutical-technology
May 17, 2021
The UK National Institute for Health and Care Excellence (NICE) has decided not to recommend ozanimod for the treatment of relapsing multiple sclerosis (MS) patients on National Health Service (NHS) in England and Wales.
NICE rejects Pfizer’s rare heart disease treatment Vyndaqel pharmatimes
May 13, 2021
Pfizer’s Vyndaqel has been rejected by the UK National Institute for Health and Care Excellence (NICE) as a treatment for the rare heart condition transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
NICE expands access for SMA drug Spinraza pharmatimes
May 07, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has extended the clinical eligibility criteria for Biogen’s spinal muscular atrophy (SMA) drug Spinraza following a review of data collected as part of a managed access agreement (MAA).
Preliminary NICE 'no' for Merck's Bavencio pharmatimes
May 07, 2021
The National Institute for Health and Care Excellence (NICE) has issued a preliminary rejection of NHS funds for use of Merck Serono's Bavencio (avelumab) as maintenance treatment of locally advanced or metastatic urothelial cancer.
NICE updates guideline on atrial fibrillation pharmatimes
April 28, 2021
The UK’s National Institute for Health and Care Excellence has published an updated clinical guideline on the diagnosis and management of atrial fibrillation (AF) addressing several areas of new evidence.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page